Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187538
Title: | Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants |
Author: | Monteil, Vanessa Eaton, Brett Postnikova, Elena Murphy, Michael Braunsfeld, Benedict Crozier, Ian Kricek, Franz Niederhofer, Janine Schwarzbock, Alice Breid, Helene Devignot, Stephanie Klingstrom, Jonas Thalin, Charlotte Kellner, Max J Christ, Wanda Havervall, Sebastian Mereiter, Stefan Knapp, Sylvia Sanchez Jimenez, Anna Bugajska-Schretter, Agnes Dohnal, Alexander Ruf, Christine Gugenberger, Romana Hagelkruys, Astrid Montserrat, Nuria Kozieradzki, Ivona Ali, Omar Hasan Stadlmann, Johannes Holbrook, Michael R Schmaljohn, Connie Oostenbrink, Chris Shoemaker, Robert H Mirazimi, Ali Wirnsberger, Gerald Penninger, Josef M |
Keywords: | Assaigs clínics COVID-19 Vacunes Clinical trials COVID-19 Vaccines |
Issue Date: | 4-Jul-2022 |
Publisher: | EMBO Press |
Citation: | Monteil, Vanessa;Eaton, Brett;Postnikova, Elena;Murphy, Michael;Braunsfeld, Benedict;Crozier, Ian;Kricek, Franz;Niederhofer, Janine;Schwarzbock, Alice;Breid, Helene;Devignot, Stephanie;Klingstrom, Jonas;Thalin, Charlotte;Kellner, Max J;Christ, Wanda;Havervall, Sebastian;Mereiter, Stefan;Knapp, Sylvia;Jimenez, Anna Sanchez;Bugajska-Schretter, Agnes;Dohnal, Alexander;Ruf, Christine;Gugenberger, Romana;Hagelkruys, Astrid;Montserrat, Nuria;Kozieradzki, Ivona;Ali, Omar Hasan;Stadlmann, Johannes;Holbrook, Michael R;Schmaljohn, Connie;Oostenbrink, Chris;Shoemaker, Robert H;Mirazimi, Ali;Wirnsberger, Gerald;Penninger, Josef M. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. Embo Molecular Medicine, 2022-e15230 |
Abstract: | The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here, we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by all current VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic. |
Note: | https://doi.org/10.15252/emmm.202115230 |
It is part of: | Embo Molecular Medicine, 2022-e15230 |
URI: | http://hdl.handle.net/2445/187538 |
Related resource: | https://doi.org/10.15252/emmm.202115230 |
Appears in Collections: | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2022_EMBOMolMed_Clinical_MontserratN.pdf | 1.82 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License